Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRO-302
- Development stage
- Unknown
- Lead developer
- Proterris
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
PRO-302 is an inhaled formulation of carbon monoxide (iCO) being developed by Proterris for the prevention of Primary Graft Dysfunction (PGD) in patients undergoing lung transplantation. The therapeutic approach leverages the cytoprotective, anti-inflammatory, and anti-apoptotic properties of carbon monoxide to mitigate ischemia-reperfusion injury (IRI), a major cause of early morbidity and mortality following organ transplantation. By delivering low doses of CO directly to the lungs, PRO-302 aims to reduce the inflammatory response and oxidative stress associated with the re-establishment of blood flow to the donor organ. The drug is currently in the early stages of clinical development, with an IND filing planned for the second half of 2025.
- Other names
- inhaled carbon monoxideiCOinhaled CO
Beyond the preview
Go deeper on PRO-302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRO-302.